Five-year Direct Costs of Acute Lymphoblastic Leukemia Pediatric Patients Undergoing Allogeneic Stem Cell Transplant

Overview

Journal Int J Hematol Oncol

Date 2018 Oct 11

PMID 30302205

Citations 5

Authors

Richard T Maziarz

Annie Guerin

Genevieve Gauthier

Julie Heroux

Maryia Zhdanava

Eric Q Wu

Simu K Thomas

Lei Chen

Affiliations

Soon will be listed here.

Abstract

Aim: To assess the 5-year healthcare resource utilization (HRU) and direct payer costs following allogeneic hematopoietic stem cell transplants (HSCTs) in acute lymphoblastic leukemia pediatric patients using data from two large US administrative databases.

Patients & Methods: Among the 209 patients with acute lymphoblastic leukemia, HRU and costs were described over the up to 5 years after the HSCT.

Results: HRU and costs following the HSCTs were substantial. The highest average costs and most intensive HRU were observed within the first year following the HSCTs (49 outpatient visits; 29 laboratory service visits; 68 inpatient days), with a first year cost of US$683,099 and substantial costs over the following years.

Conclusion: HRU and direct costs associated with allogeneic HSCTs are substantial.

Citing Articles

A new beginning: can omidubicel emerge as the next, viable alternative donor source?.

Gandhi A, Newell L, Maziarz R Ther Adv Hematol. 2023; 14:20406207231192146.

PMID: 37664800 PMC: 10469227. DOI: 10.1177/20406207231192146.

Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective.

Wang X, Wang Y, Ong M, Gkitzia C, Soh S, Hwang W Clinicoecon Outcomes Res. 2022; 14:333-355.

PMID: 35535300 PMC: 9078873. DOI: 10.2147/CEOR.S355557.

Utilisation and outcomes of allogeneic hematopoietic cell transplantation in Ontario, Canada, and New York State, USA: a population-based retrospective cohort study.

Hershenfeld S, Matelski J, Ling V, Paterson M, Cheung M, Cram P BMJ Open. 2020; 10(10):e039293.

PMID: 33130568 PMC: 7783612. DOI: 10.1136/bmjopen-2020-039293.

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.

Yang H, Hao Y, Qi C, Chai X, Wu E J Manag Care Spec Pharm. 2020; 26(8):971-980.

PMID: 32525730 PMC: 10391202. DOI: 10.18553/jmcp.2020.20052.

The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

Braendstrup P, Levine B, Ruella M Cytotherapy. 2020; 22(2):57-69.

PMID: 32014447 PMC: 7036015. DOI: 10.1016/j.jcyt.2019.12.004.

References

Swensen A, Birnbaum H, Secnik K, Marynchenko M, Greenberg P, Claxton A . Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry. 2003; 42(12):1415-23. DOI: 10.1097/00004583-200312000-00008. View

Oliansky D, Rizzo J, Aplan P, Arceci R, Leone L, Ravindranath Y . The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2007; 13(1):1-25. DOI: 10.1016/j.bbmt.2006.10.024. View

LeMaistre C, Farnia S, Crawford S, McGuirk J, Maziarz R, Coates J . Standardization of terminology for episodes of hematopoietic stem cell patient transplant care. Biol Blood Marrow Transplant. 2013; 19(6):851-7. DOI: 10.1016/j.bbmt.2013.03.004. View

Talano J, Pulsipher M, Symons H, Militano O, Shereck E, Giller R . New frontiers in pediatric Allo-SCT. Bone Marrow Transplant. 2014; 49(9):1139-45. PMC: 4439009. DOI: 10.1038/bmt.2014.89. View

Wingard J, Majhail N, Brazauskas R, Wang Z, Sobocinski K, Jacobsohn D . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230-9. PMC: 3107742. DOI: 10.1200/JCO.2010.33.7212. View

Castagnola E, Bagnasco F, Bandettini R, Caviglia I, Morreale G, Lanino E . Role of acute graft-versus-host disease in the risk of bacteremia and invasive fungal disease after allogeneic hemopoietic stem cell transplantation in children. Results from a single-center observational study. Biol Blood Marrow Transplant. 2014; 20(7):1068-73. DOI: 10.1016/j.bbmt.2014.03.026. View

Saito A, Cutler C, Zahrieh D, Soiffer R, Ho V, Alyea E . Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008; 14(2):197-207. PMC: 2259445. DOI: 10.1016/j.bbmt.2007.10.010. View

Frangoul H, Najjar J, Simmons J, Domm J . Long-term follow-up and management guidelines in pediatric patients after allogenic hematopoietic stem cell transplantation. Semin Hematol. 2012; 49(1):94-103. DOI: 10.1053/j.seminhematol.2011.10.012. View

Ouyang L, Grosse S, Armour B, Waitzman N . Health care expenditures of children and adults with spina bifida in a privately insured U.S. population. Birth Defects Res A Clin Mol Teratol. 2007; 79(7):552-8. DOI: 10.1002/bdra.20360. View

10.

Wei C, Albanese A . Endocrine Disorders in Childhood Cancer Survivors Treated with Haemopoietic Stem Cell Transplantation. Children (Basel). 2016; 1(1):48-62. PMC: 4939518. DOI: 10.3390/children1010048. View

11.

Preussler J, Denzen E, Majhail N . Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18(11):1620-8. PMC: 3678555. DOI: 10.1016/j.bbmt.2012.04.001. View

12.

Jesudas R, Malesky A, Chu R, Fischer H, Kamat D . Reviewing the follow-up care of pediatric patients' status post-hematopoietic stem cell transplantation for the primary care pediatrician. Clin Pediatr (Phila). 2013; 52(6):487-95. DOI: 10.1177/0009922813483361. View

13.

Svahn B, Alvin O, Ringden O, Gardulf A, Remberger M . Costs of allogeneic hematopoietic stem cell transplantation. Transplantation. 2006; 82(2):147-53. DOI: 10.1097/01.tp.0000226171.43943.d3. View

14.

Nash R, Antin J, Karanes C, Fay J, Avalos B, Yeager A . Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000; 96(6):2062-8. View

15.

Saito A, Zahrieh D, Cutler C, Ho V, Antin J, Soiffer R . Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007; 40(3):209-17. DOI: 10.1038/sj.bmt.1705733. View

16.

Ishaqi M, Afzal S, Dupuis A, Doyle J, Gassas A . Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant. 2007; 41(3):245-52. DOI: 10.1038/sj.bmt.1705891. View

17.

Lin Y, Lairson D, Chan W, Du X, Leung K, Kennedy-Nasser A . The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010; 16(9):1272-81. PMC: 2919628. DOI: 10.1016/j.bbmt.2010.03.016. View

18.

Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R . Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015; 33(11):1275-84. DOI: 10.1200/JCO.2014.58.4631. View

19.

Bachanova V, Sandhu K, Yohe S, Cao Q, Burke M, Verneris M . Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood. 2011; 117(19):5261-3. PMC: 3109547. DOI: 10.1182/blood-2011-01-329573. View

20.

Rives S, Estella J, Gomez P, Lopez-Duarte M, Garcia de Miguel P, Verdeguer A . Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish.... Br J Haematol. 2011; 154(5):600-11. DOI: 10.1111/j.1365-2141.2011.08783.x. View